{"log_id": 3676225938899487743, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0.024122, "average": 0.929192, "min": 0.374832}, "location": {"width": 834, "top": 169, "height": 41, "left": 160}, "words": ":本上无例外企为白种男性,同性恋,平均年龄为38岁,AIDS晚期,扩展性卡波氏"}, {"probability": {"variance": 0.020686, "average": 0.94589, "min": 0.401995}, "location": {"width": 833, "top": 219, "height": 41, "left": 158}, "words": "肉,表现为CD4细胞数低临床试验组中AlDS病人多数为低危病人)。参加试验的病人"}, {"probability": {"variance": 0.042138, "average": 0.892855, "min": 0.394506}, "location": {"width": 450, "top": 270, "height": 32, "left": 158}, "words": "在滋病相关的卡波氏肉瘤病人中具有代表性"}, {"probability": {"variance": 0.015403, "average": 0.958596, "min": 0.416748}, "location": {"width": 782, "top": 320, "height": 39, "left": 206}, "words": "247例病人参加的第一项研究是以盐酸多柔比星脂质体进行的无对照开放的多中心"}, {"probability": {"variance": 0.001634, "average": 0.984358, "min": 0.77951}, "location": {"width": 833, "top": 368, "height": 41, "left": 156}, "words": "试验:游人接受的平均剂量为20mg/m2,共接受2015个治疗周期,治疗间隔为2周。临床"}, {"probability": {"variance": 0.001119, "average": 0.988883, "min": 0.842801}, "location": {"width": 447, "top": 420, "height": 31, "left": 154}, "words": "终点包括治疗反应和生活质量。该研究结果如下"}, {"probability": {"variance": 5.5e-05, "average": 0.992039, "min": 0.978297}, "location": {"width": 151, "top": 468, "height": 24, "left": 298}, "words": "完全缓解(CR)"}, {"probability": {"variance": 0, "average": 0.999407, "min": 0.998838}, "location": {"width": 28, "top": 478, "height": 19, "left": 800}, "words": "3%"}, {"probability": {"variance": 5.1e-05, "average": 0.993873, "min": 0.976689}, "location": {"width": 152, "top": 509, "height": 23, "left": 297}, "words": "部分缓解(PR)"}, {"probability": {"variance": 0.005165, "average": 0.955055, "min": 0.813554}, "location": {"width": 46, "top": 518, "height": 20, "left": 779}, "words": "74.4%"}, {"probability": {"variance": 0.000391, "average": 0.987854, "min": 0.948571}, "location": {"width": 94, "top": 549, "height": 25, "left": 316}, "words": "稳定(SD"}, {"probability": {"variance": 8.9e-05, "average": 0.992746, "min": 0.97665}, "location": {"width": 42, "top": 559, "height": 21, "left": 783}, "words": "8.5%"}, {"probability": {"variance": 3e-06, "average": 0.99826, "min": 0.993992}, "location": {"width": 153, "top": 593, "height": 25, "left": 295}, "words": "疾病进展(PD)"}, {"probability": {"variance": 2.5e-05, "average": 0.99585, "min": 0.987341}, "location": {"width": 47, "top": 602, "height": 21, "left": 778}, "words": "0.8%"}, {"probability": {"variance": 0.000189, "average": 0.995767, "min": 0.916886}, "location": {"width": 785, "top": 635, "height": 42, "left": 197}, "words": "在进行的长期随访中,仅有部分病人接受上市推荐的用药方案,对不同用药方案的疗"}, {"probability": {"variance": 3.9e-05, "average": 0.996781, "min": 0.968165}, "location": {"width": 835, "top": 684, "height": 41, "left": 149}, "words": "效反应进行统计学分析,差异不显著。到目前为止,平均缓解持续时间为117天,与疼痛相"}, {"probability": {"variance": 0.005047, "average": 0.976253, "min": 0.741166}, "location": {"width": 253, "top": 735, "height": 28, "left": 150}, "words": "关的生活质量数据有所改善"}, {"probability": {"variance": 0.001986, "average": 0.989964, "min": 0.725209}, "location": {"width": 828, "top": 777, "height": 48, "left": 195}, "words": "37例与艾滋病相关的卡波氏肉瘤病人参加的第二项研究是无对照开放试验盐酸多柔"}, {"probability": {"variance": 0.008607, "average": 0.976199, "min": 0.383032}, "location": {"width": 835, "top": 827, "height": 44, "left": 143}, "words": "比脂质体的中位剂量为20mg/m2,3周重复一次,共进行793个治疗周期,中位累计剂量"}, {"probability": {"variance": 0.005105, "average": 0.944079, "min": 0.798037}, "location": {"width": 216, "top": 880, "height": 25, "left": 146}, "words": "为110mg/m,有效率如"}, {"probability": {"variance": 0.053195, "average": 0.855213, "min": 0.36292}, "location": {"width": 130, "top": 927, "height": 23, "left": 286}, "words": "先全缓解(C"}, {"probability": {"variance": 0.000143, "average": 0.988023, "min": 0.976064}, "location": {"width": 29, "top": 937, "height": 20, "left": 782}, "words": "0%"}, {"probability": {"variance": 0.000443, "average": 0.988547, "min": 0.933652}, "location": {"width": 152, "top": 967, "height": 26, "left": 286}, "words": "部分缓解(PR)"}, {"probability": {"variance": 0.000453, "average": 0.986297, "min": 0.944027}, "location": {"width": 49, "top": 978, "height": 21, "left": 767}, "words": "61.8%"}, {"probability": {"variance": 0.000271, "average": 0.987646, "min": 0.956473}, "location": {"width": 96, "top": 1010, "height": 22, "left": 306}, "words": "稳定(SD"}, {"probability": {"variance": 0.002448, "average": 0.974394, "min": 0.87544}, "location": {"width": 53, "top": 1019, "height": 21, "left": 769}, "words": "26.5%"}, {"probability": {"variance": 0.000593, "average": 0.988046, "min": 0.928835}, "location": {"width": 138, "top": 1049, "height": 25, "left": 284}, "words": "疾病进展(PD"}, {"probability": {"variance": 0.002347, "average": 0.95263, "min": 0.874993}, "location": {"width": 56, "top": 1060, "height": 21, "left": 766}, "words": "1].8%"}, {"probability": {"variance": 0.000952, "average": 0.989262, "min": 0.815274}, "location": {"width": 788, "top": 1091, "height": 43, "left": 186}, "words": "从有效性和所有病人(包括以前接受过化疗的)疼痛的减轻来看,从该研究获得的结"}, {"probability": {"variance": 0.007454, "average": 0.979218, "min": 0.464278}, "location": {"width": 834, "top": 1138, "height": 43, "left": 138}, "words": "果是令人鼓舞的,中位缓解持续时间为92天。截至研究结束时,共有37例病人死亡,生存"}, {"probability": {"variance": 0.034985, "average": 0.899183, "min": 0.422043}, "location": {"width": 187, "top": 1189, "height": 26, "left": 138}, "words": "期的延长效果不显"}, {"probability": {"variance": 0.00892, "average": 0.975479, "min": 0.437199}, "location": {"width": 788, "top": 1237, "height": 42, "left": 182}, "words": "两研究的分析根据白血球减少症、全身性疾病(包括机会性感染)CD4细胞数进行"}, {"probability": {"variance": 0.012699, "average": 0.942328, "min": 0.48941}, "location": {"width": 815, "top": 1284, "height": 44, "left": 157}, "words": "调整,并发现原患有粒细胞减少症的病人(ANC<200 cells/mn3)的整体反应率(69.3%)"}, {"probability": {"variance": 0.004617, "average": 0.980241, "min": 0.560058}, "location": {"width": 804, "top": 1333, "height": 43, "left": 153}, "words": "粒细胞基础水平高的患者相同(76.6%)。同样,全身性疾病基础水平风险高的病人(79%"}, {"probability": {"variance": 0.014443, "average": 0.95492, "min": 0.458425}, "location": {"width": 828, "top": 1382, "height": 42, "left": 137}, "words": "小低风险的病人(68%)的治疗反应率也相似。CD4计数有关的情况是:CD4数量<"}, {"probability": {"variance": 0, "average": 0.803482, "min": 0.803482}, "location": {"width": 57, "top": 1433, "height": 20, "left": 134}, "words": " Socells"}, {"probability": {"variance": 0.027112, "average": 0.862017, "min": 0.539564}, "location": {"width": 183, "top": 1433, "height": 27, "left": 239}, "words": "和CD4>50cl"}, {"probability": {"variance": 0.017, "average": 0.951102, "min": 0.435278}, "location": {"width": 331, "top": 1436, "height": 32, "left": 477}, "words": "的病人反应率相似。然而,<50cl"}, {"probability": {"variance": 2e-06, "average": 0.998401, "min": 0.996113}, "location": {"width": 106, "top": 1444, "height": 25, "left": 857}, "words": "的患者中有"}, {"probability": {"variance": 0.013576, "average": 0.962475, "min": 0.442637}, "location": {"width": 520, "top": 1478, "height": 37, "left": 137}, "words": "%个缓解,而CD4水平最高的患者中有10%完全缓解"}, {"probability": {"variance": 0.009498, "average": 0.959998, "min": 0.510097}, "location": {"width": 789, "top": 1525, "height": 47, "left": 174}, "words": "为了充分证明盐酸多柔比早脂质体的有效性,进行了盐酸多柔比早脂质体(20mg/m2"}, {"probability": {"variance": 0.024178, "average": 0.903991, "min": 0.365524}, "location": {"width": 828, "top": 1574, "height": 47, "left": 130}, "words": "与ABV多柔比星(20mg/m3)、博莱霉素(10U/m2)及长春新碱1mg/m2)]的前膽性随机"}], "language": 3}